A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

Abstract Background Combination therapy involving immune checkpoint blockade (ICB) and other drugs is a potential strategy for converting immune-cold tumors into immune-hot tumors to benefit from immunotherapy. To achieve drug synergy, we developed a homologous cancer cell membrane vesicle (CM)-coat...

Full description

Bibliographic Details
Main Authors: Zhenzhen Jiang, Guangqing Cai, Haiting Liu, Leping Liu, Rong Huang, Xinmin Nie, Rong Gui, Jian Li, Jinqi Ma, Ke Cao, Yanwei Luo
Format: Article
Language:English
Published: BMC 2024-05-01
Series:Journal of Nanobiotechnology
Subjects:
Triple-negative breast cancer (TNBC)
Metal-organic framework
Immunogenic cell death
BET inhibitor
Biomimetic codelivery system
Tumor immune microenvironment
Online Access:https://doi.org/10.1186/s12951-024-02525-1

Internet

https://doi.org/10.1186/s12951-024-02525-1

Similar Items